Navigating the impact of COVID-19 on the commercial life sciences industry

What you need to know

Life sciences, medical device and pharmaceutical organizations are going through rapid change as they adapt to the new pressures and complexities caused by the COVID-19 pandemic. While navigating disruptions and adapting to the new normal, the life sciences industry is devoting significant attention to identifying initiatives that will aid in effectively running their business under the new set of circumstances.

Download Baker Tilly’s educational, complimentary white paper to learn how life sciences companies are:

• Navigating clinical trial delays and disruptions
• Adapting to long-term supply chain issues
• Adhering to federal funding compliance requirements
• Responding to alternative means to field-based sales and education practices

For more information about population health platforms, or to learn how Baker Tilly’s life sciences industry Value Architects™ can help, contact our team.